BerryS., CunninghamD., MichaelM.: Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for metastatic colorectal cancer.First BEAT trial. Proc ASCO2006, abstract 3534.
2.
HedrickE., KozloffM., HainsworthJ.: Safety of bevacizumab as first line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE).Proc ASCO2006, abstract 3536.
3.
HurwitzH., FehrehnbacherL., NovotnyW.: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer.N Engl J Med2004; 350: 2335–2342.
4.
SaltzL.B., ChungK.Y., TimoneyJ.: Simplification of bevacizumab administration: do we need 90, 60 or even 30 minute infusion times?Proc ASCO2006, abstract 3542.
5.
KozloffM., HainsworthJ., BadarinathS.: Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE).Proc ASCO2006, abstract 3537.
6.
KabbinavarF., ZurloA., IrlC.: Bevacizumab improves outcomes of patients with metastatic colorectal cancer treated with IFL with or without bevacizumab independent of baseline risk.Proc ASCO2006, abstract 3539.
7.
KoehneC.H., CunninghamD., Di CostanzoF.: Clinical determinants of survival in patients with 5FU-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.Ann Oncol2002; 13: 308–317.
8.
SobreroA., AcklandS., CarrionR.P.: Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5FU as first-line treatment of patients with metastatic colorectal cancer.Proc ASCO2006, abstract 3544.
9.
KopetzS., AbbruzzeseJ.L., EngC.: Preliminary results from a phase II study of infusional 5FU, leucovorin and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment of metastatic colorectal cancer.Proc ASCO2006, abstract 3579.
10.
TournigandC., AndréT., AchilleE.: FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.J Clin Oncol2004, 22: 229–237.
11.
SchuellerJ., CzejkaM., KissA.: Influence of bevacizumab on the plasma disposition of CPT11 and its metabolites in advanced colorectal cancer patients.Proc ASCO2006, abstract 3540.
12.
FuchsC., MarshallJ., MitchellE.: A randomized trial of first-line irinotecan/flouropyrimidine combinations with or without celecoxib in mCRC (BICC-C).Proc ASCO2006, abstract 3506.
13.
HochsterH.S., HartL.L., RamanthanR.K.: Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of mCRC: final anlysis of the TREE study.Proc ASCO2006, abstract 3510.
14.
HochsterH.S., WellesL., HartL.: Safety and efficacy of bevacizumab when added to oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer: TREE 1 and 2 studies.Proc ASCO2005, abstract 3515.
15.
EllisL.M., CurleyS.A., GrotheyA.: Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab.J Clin Oncol2005; 23: 4853–4855.
16.
GruenbergerB., ScheitauerW., TamandiD.: Neoadjuvant chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer.Proc ASCO2006, abstract 3546.
17.
MichaelM., Van CutsemE., KretzschmarA.: Feasibility of metastasectomy in patients treated with bevacizumab in first-line metastatic colorectal cancer therapy: preliminary results from the first BEAT study.Proc ASCO2006, abstract 3523.
